Foster Wheeler has been awarded an engineering, procurement and construction (EPC) contract for Phase 2 of Schering-Plough’s multi-product active pharmaceutical ingredient plant (MPP2) in Tuas, Singapore. The contract, which is valued at USD 150 million, will be executed jointly by Foster Wheeler’s pharmaceutical centres of excellence in Reading, UK and Singapore. The plant is a “smart clone” of the MPP1 (multi-product plant) project that Foster Wheeler is currently finishing for Schering-Plough, also in Singapore. The plant will produce the cholesterol-lowering agent, ZETIA (ezetimibe) Tablets. Foster Wheeler was awarded the contract based on the planned completion of MPP1.
Looking for more projects or tenders?
Subscribe to our Project Preview Newsletter
